Aspirin use and long-term rates of sepsis: A population-based cohort study

Joann Hsu¹, John P. Donnelly²,³,⁴, Ninad S. Chaudhary²,⁴, Justin X. Moore²,⁴, Monika M. Safford⁵, Junghyun Kim⁶, Henry E. Wang²,⁶*

¹ University of Alabama School of Medicine, Birmingham, Alabama, United States of America, ² Department of Emergency Medicine, University of Alabama School of Medicine, Birmingham, Alabama, United States of America, ³ Division of Preventive Medicine, Department of Medicine, University of Alabama School of Medicine, Birmingham, Alabama, United States of America, ⁴ Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, ⁵ Department of Medicine, Weill Cornell Medical College, New York, NY, United States of America, ⁶ Department of Emergency Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America

* henry.e.wang@uth.tmc.edu

Abstract

Objective

Sepsis is the syndrome of life-threatening organ dysfunction resulting from dysregulated host response to infection. Aspirin, an anti-inflammatory agent, may play a role in attenuating the inflammatory response during infection. We evaluated the association between aspirin use and long-term rates of sepsis as well as sepsis outcomes.

Methods

We analyzed data from 30,239 adults ≥45 years old in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. The primary exposure was aspirin use, identified via patient interview. The primary outcome was sepsis hospitalization, defined as admission for infection with two or more systemic inflammatory response syndrome criteria. We fit Cox proportional hazards models assessing the association between aspirin use and rates of sepsis, adjusted for participant demographics, health behaviors, chronic medical conditions, medication adherence, and biomarkers. We used a propensity-matched analysis and a series of sensitivity analyses to assess the robustness of our results. We also examined risk of organ dysfunction and hospital mortality during hospitalization for sepsis.

Results

Among 29,690 REGARDS participants with follow-up data available, 43% reported aspirin use (n = 12,869). Aspirin users had higher sepsis rates (hazard ratio 1.35; 95% CI: 1.22–1.49) but this association was attenuated following adjustment for potential confounders (adjusted HR 0.99; 95% CI: 0.88–1.12). We obtained similar results in propensity-matched and sensitivity analyses. Among sepsis hospitalizations, aspirin use was not associated with organ dysfunction or hospital death.
Conclusions
In the REGARDS cohort, baseline aspirin use was not associated with long-term rates of sepsis.

Introduction
Sepsis is the syndrome of life-threatening organ dysfunction resulting from dysregulated host response to infection [1]. In the United States (US), sepsis is responsible for over 665,000 hospital admissions, 850,000 Emergency Department visits and 215,000 deaths annually [2, 3]. Current recommendations for treating sepsis are primarily aimed at recognition and management [4, 5]. Studies of other acute conditions, such as myocardial infarction (MI) and stroke, have highlighted the importance of prevention as a potential strategy for reducing the public health burden of fatal diseases. However, there have been few organized efforts targeting sepsis prevention.

Aspirin is an irreversible inhibitor of the enzyme cyclooxygenase, a key component in the activation of inflammatory pathways through the production of prostaglandins [6]. Aspirin therapy has been widely used for treating and preventing vascular diseases such as myocardial infarction and stroke [6–11]. The use of aspirin as a preventive therapy for sepsis is plausible and feasible. Sepsis impairs the hemostatic function of platelets, potentially mitigating hypercoagulability found in acute sepsis [12–14]. A limited body of research suggests that prior antiplatelet use is associated with decreased risk of mortality from sepsis [15–19]. There is limited knowledge of the association between baseline aspirin use and incidence of sepsis, and prior studies have been unable to link incident events with hospitalization outcomes [20, 21].

Similar to the effects seen in diseases such as MI and stroke, regular aspirin use could offer a potential sepsis prevention strategy. A better understanding of the association between regular aspirin use and long-term sepsis risk could set the stage for its use to prevent acute sepsis.

The Reasons for Geographic and Racial Differences in Stroke (REGARDS) is one of the nation’s largest population-based cohort studies, providing longitudinal data from community-dwelling individuals over a ten-year period. Using REGARDS data, we sought to determine if aspirin use is associated with long-term rates of sepsis.

Methods
Study design
We performed a prospective cohort study using data from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort [22]. This study was approved by the Institutional Review Board of the University of Alabama at Birmingham.

The REGARDS cohort
The REGARDS cohort is one of the nation’s largest population-based cohorts of community-dwelling adults. The parent study was designed to identify factors associated with racial and regional differences in stroke mortality. Between January 2003 and October 2007, 30,239 individuals aged 45 years or older were recruited. Participants were oversampled from the Southeastern US, with 30% of the participants recruited from the “Stroke Belt” (defined as the coastal plains of North Carolina, South Carolina, and Georgia), and 20% from the “Stroke Buckle” (the remainder of North Carolina, South Carolina, and Georgia, plus Tennessee, Mississippi, Alabama, Louisiana, and Arkansas). The cohort is 45% male and 42% African American and does not include Hispanics.
REGARDS collected baseline information on participant through telephone interviews and in-person assessments. Baseline information collected on each participant included medical and personal histories, demographic data, health behaviors, physical measures and vital signs, and a medication inventory. Blood and urine specimens were also collected from participants. Every six months, trained interviewers telephoned each participant to obtain updated information on all hospitalizations since the last follow-up call.

**Identification of aspirin use**

REGARDS study personnel ascertained aspirin use during baseline subject enrollment in the study. We defined aspirin use based upon responses to the question, “Are you currently taking aspirin or aspirin containing products regularly, that is, at least two times each week?” REGARDS did not ascertain the reasons for aspirin use.

**Identification of sepsis events**

The primary endpoint was hospitalization for sepsis. We identified all hospitalizations and Emergency Department visits attributed to a serious infection. To verify the presence of serious infection at admission and infection as a primary reason for hospitalization, two abstractors independently reviewed all relevant medical records. Abstractor agreement and additional physician-level review resolved any discordances. Sepsis was defined as infection at hospital presentation plus two or more systemic inflammatory response syndrome (SIRS) criteria, which include 1) heart rate >90 beats/minute, 2) fever (temperature >38.3°C or <36°C), 3) tachypnea (>20 breaths/min) or PCO$_2$<32 mmHg, and 4) leukocytosis (white blood cells [WBC] >12,000 or <4,000 cells/mm$^3$ or >10% band forms).

We assessed vital signs and laboratory findings within the first 28-hours of hospitalization to include Emergency Department care and up to one full day of inpatient care. Because the analysis focused on community-acquired sepsis, we did not assess vital signs, laboratory findings, or development of sepsis at later time points. Initial review of 1,329 hospital records indicated excellent inter-rater consensus for the presence of serious infection (kappa = 0.92) and the presence of sepsis (kappa = 0.90) at the time of hospital presentation.

We did not include organ dysfunction in the primary definition of sepsis. In secondary analyses, we did evaluate death occurring during sepsis hospitalization.

**Covariates**

We examined demographics, health behaviors, chronic medical conditions, Morisky medication adherence, and biomarkers as possible confounding variables in the relationship between aspirin use and sepsis. Demographic characteristics included age, sex, race, geographic region, annual household income, and highest level of education achieved. Health behaviors included smoking status and alcohol use. Chronic medical conditions included history of MI, coronary artery disease, atrial fibrillation, hypertension, stroke, chronic kidney disease, peripheral artery disease, chronic lung disease, deep vein thrombosis, dyslipidemia, diabetes, and obesity (S1 Table). Biomarkers considered potential risk factors for sepsis included hsCRP and ACR [23, 24]. REGARDS used a four-question version of the Morisky Medical Adherence Scale to determine participant’s medication compliance [25] (S2 Table). We defined medication adherence as 0 = good, 1 = fair, and 2–4 = poor.
Data analysis

We used Pearson chi-square tests of association and t-tests of equal means to evaluate differences in participant characteristics between baseline aspirin users and non-users.

In order to assess the association between aspirin use and sepsis rates, we fit a set of multivariable Cox proportional hazards models, adjusting for demographics (age, sex, income race, geographical region, education), health behaviors (tobacco and alcohol use), chronic medical conditions (diabetes, hypertension, dyslipidemia, stroke, coronary artery disease, atrial fibrillation, deep vein thrombosis, peripheral artery disease, chronic kidney disease, chronic lung disease, obesity), Morisky Medication Adherence, and biomarkers (ACR, hsCRP). We verified the proportional hazards assumption using Schoenfeld residuals and tests of the interaction with the logarithm of follow-up time.

To evaluate the robustness of our results, we conducted a series of sensitivity analyses. We first repeated the analysis limited to sepsis events due lung, kidney and abdominal infections (the most common infection types). Because aspirin use may vary with risk of heart disease, we repeated the analysis stratified by a) history coronary artery disease (CAD) and b) Framingham Coronary Heart Disease (CHD) Risk Scores <10%, 10–20%, and >20%) [26].

Because aspirin use might be more likely among individuals with high comorbid illness burden, we defined a propensity score for baseline aspirin use for each participant using a logistic regression model and including the maximum number of covariates that would give a balance of factors between users and non-users [8–11, 27–29]. Specifically, the model included age, sex, race, region, education, smoking status, alcohol use, chronic kidney disease, chronic lung disease, deep vein thrombosis, dyslipidemia, hypertension, obesity, peripheral artery disease, CRP, Morisky Adherence Scale, and ACR [27]. We matched aspirin users and non-users 1:1 based upon propensity score, using nearest neighbor matching with a caliper equal to 30% of the standard deviation of the logit [30]. All analyses of the propensity-matched cohort were stratified by pair, to account for non-independence introduced by matching. We also assessed the association between aspirin use and sepsis incidence stratified by propensity score tertile [27, 31].

We repeated the analysis stratified by Morisky medication adherence classes. Finally, we performed a competing risks analysis, modeling all cause death as a competing event. Among first-sepsis hospitalizations, we also evaluated the associations between aspirin use and sepsis hospital death. In order to prevent over-fitting of the multivariable models, we included only hospital variables that were statistically significant on univariate analysis. We performed all analyses using Stata version 14.1 (Stata, Inc., College Station, Texas).

Results

Out of 30,239 REGARDS participants, we included 29,690 with follow-up information available. Among these participants, 12,869 (43%) reported baseline aspirin use (Table 1). The median follow-up time was 6.2 years (IQR 5.1–8.1 years). Aspirin users were older at baseline and more likely to be male and white compared to non-users. Aspirin users were also more likely to have chronic medical conditions and to report good medication adherence.

There were a total of 1,526 first sepsis events in this population. Of these hospitalizations, 1,122 (73.5%) presented with severe sepsis and 140 (9.2%) resulted in hospital death. The most common infection types associated with sepsis were lung, kidney and abdominal infections. (Table 2)

In unadjusted analyses, aspirin use was associated with increased rates of sepsis (Table 3: HR 1.35; 95% CI: 1.22–1.49) (Fig 1). However, after multivariable adjustment for potential confounding factors, the association between aspirin use and sepsis was attenuated (adjusted HR 1.00; 95% CI: 0.90–1.13).
Table 1. Characteristics of REGARDS participants, stratified by aspirin use.

| Characteristic       | AspirinUser (n = 12,869) | AspirinNon-User (n = 16,821) | p-value |
|----------------------|--------------------------|-----------------------------|---------|
| **DEMOGRAPHICS**     |                          |                             |         |
| Age (mean ± SD)      | 66.7 ± 8.9               | 63.5±9.6                    | <0.001  |
| Sex                  |                          |                             | <0.001  |
| Male                 | 6,715 (52.2)             | 6,619 (39.4)                |         |
| Female               | 6,154 (47.8)             | 10,202 (60.7)               |         |
| Race                 |                          |                             | <0.001  |
| White                | 8,171 (63.5)             | 9,302 (55.3)                |         |
| Black                | 4,698 (36.5)             | 7,519 (44.7)                |         |
| Income               |                          |                             | 0.189   |
| <$20,000             | 2,313 (18.0)             | 3,030 (18.0)                |         |
| $20,000–34,000       | 3,165 (24.6)             | 4,008 (23.8)                |         |
| $35,000–74,000       | 3,778 (29.4)             | 5,031 (29.9)                |         |
| ≥ $75,000            | 2,071 (16.1)             | 2,626 (15.6)                |         |
| Unknown              | 1,542 (12.0)             | 2,126 (12.6)                |         |
| Education            |                          |                             | <0.001  |
| Less than high school| 1,678 (13.1)             | 2,031 (12.1)                |         |
| High school graduate | 3,288 (25.6)             | 4,378 (26.1)                |         |
| Some college         | 3,290 (25.6)             | 4,660 (27.7)                |         |
| College or Higher    | 4,602 (35.8)             | 5,740 (34.2)                |         |
| Missing              | 11 (0.1)                 | 12 (0.1)                    |         |
| Region               |                          |                             | <0.001  |
| Belt                 | 4,421 (34.4)             | 5,864 (34.9)                |         |
| Buckle               | 2,831 (22.0)             | 3,384 (20.1)                |         |
| Nonbelt              | 5,617 (43.7)             | 7,573 (45.0)                |         |
| **HEALTH BEHAVIORS** |                          |                             |         |
| Tobacco Use          |                          |                             | <0.001  |
| Current              | 1,705 (13.3)             | 2,580 (15.4)                |         |
| Past                 | 5,723 (44.6)             | 6,197 (37.0)                |         |
| Never                | 5,402 (43.1)             | 7,979 (47.7)                |         |
| Missing              | 39 (0.3)                 | 75 (0.5)                    |         |
| Alcohol Use          |                          |                             | <0.001  |
| Heavy                | 513 (4.1)                | 664 (4.0)                   |         |
| Moderate             | 4,427 (35.1)             | 5,265 (31.9)                |         |
| None                 | 7,677 (60.9)             | 10,564 (64.1)               |         |
| Missing              | 252 (2.0)                | 328 (2.0)                   |         |
| **Chronic Medical Conditions** |          |                             |         |
| Coronary Artery Disease | 3,649 (28.9)         | 1,582 (9.6)                 | <0.001  |
| Atrial Fibrillation  | 1,274 (10.2)             | 1,275 (7.8)                 | <0.001  |
| Diabetes             | 3,652 (28.5)             | 3,052 (18.2)                | <0.001  |
| Hypertension         | 8,687 (67.7)             | 8,859 (52.8)                | <0.001  |
| Chronic Kidney Disease | 1,765 (13.7)          | 1,484 (8.8)                 | <0.001  |
| Peripheral Artery Disease | 408 (3.2)           | 256 (1.5)                   | <0.001  |
| Stroke               | 1,149 (9.0)              | 757 (4.5)                   | <0.001  |
| Obesity              | 7,066 (55.0)             | 8,798 (52.4)                | <0.001  |
| Chronic Lung Disease | 1,296 (10.1)             | 1,435 (9.5)                 | <0.001  |
| Deep Vein Thrombosis | 757 (5.9)                | 798 (4.8)                   | <0.001  |
(Continued)
Sensitivity analyses verified the primary results. When repeating the analysis limited to sepsis due to lung, kidney and abdominal infections, we observed similar results (adjusted HR 1.01; 95% CI: 0.88–1.15). On stratification by Framingham CHD Risk Score, we found that the association between aspirin use and sepsis were similar between CHD risk groups. (Table 3)

In the propensity-matched analysis, there were a total of 8,923 aspirin users matched 1:1 with non-aspirin users. In the matched cohort, there was no association between aspirin use and rates of sepsis (HR 0.97; 95% CI: 0.85–1.11). We also found no association between aspirin use and sepsis after stratifying by propensity score and Morisky medication adherence. (Table 4) When considering all cause death as a competing risk to sepsis hospitalization, the association between aspirin and sepsis was not statistically significant. Among first sepsis hospitalizations, aspirin use was not associated with sepsis or sepsis hospital death (adjusted HR 0.96; 95% CI: 0.66–1.40).

Discussion

Using data from the REGARDS study, a large population-based cohort of community-dwelling adults in the US, we found no association between aspirin use at baseline and long-term

| Characteristic                           | AspirinUser (n = 12,869) | AspirinNon-User (n = 16,821) | p-value |
|-----------------------------------------|--------------------------|-----------------------------|---------|
| Dyslipidemia                            | 8,466 (67.8)             | 8,495 (52.8)                | <0.001  |
| **BIOMARKERS**                          |                          |                             |         |
| **High Sensitivity C-Reactive Protein (hsCRP)** |                          |                             | <0.001  |
| hsCRP >3.0                              | 4,666 (38.6)             | 6,620 (42.1)                |         |
| Missing                                 | 793 (6.2)                | 1,105 (6.6)                 |         |
| **Albumin-to-Creatinine Ratio (ACR)**   |                          |                             | <0.001  |
| ACR ≥ 30                                | 2,063 (16.8)             | 2,244 (14.0)                |         |
| Missing                                 | 600 (4.7)                | 806 (4.8)                   |         |
| **Morisky Medical Adherence Scale**     |                          |                             | <0.001  |
| 0 (good)                                | 8,640 (70.6)             | 10,313 (70.0)               |         |
| 1 (fair)                                | 2,807 (22.9)             | 3,167 (21.5)                |         |
| 2–4 (poor)                              | 795 (6.5)                | 1,248 (8.5)                 |         |
| Missing                                 | 627 (4.9)                | 2,093 (12.4)                |         |

https://doi.org/10.1371/journal.pone.0194829.t001

Table 2. Infection types of first-sepsis hospitalizations, stratified by aspirin use. Total of 1,526 first sepsis cases.

| Infection Type             | n (%) |
|----------------------------|-------|
| Pneumonia                  | 601 (39.4) |
| Urinary Tract Infections   | 260 (17.0) |
| Abdominal                  | 231 (15.1) |
| Bronchitis                 | 137 (9.0) |
| Skin                       | 122 (8.0) |
| Sepsis                     | 103 (6.8) |
| Fever of unknown origin    | 29 (1.9) |
| Catheter                   | 6 (0.4)  |
| Surgical                   | 10 (0.7) |
| Meningitis                 | 5 (0.3)  |
| Other/Unknown              | 22 (1.4) |

https://doi.org/10.1371/journal.pone.0194829.t002
rates of sepsis after adjustment for demographics, health behaviors, chronic medical conditions, and biomarkers. Furthermore, among first sepsis events, we found no association between aspirin use prior to hospitalization and odds of sepsis hospital death.

Prior studies investigating the influence of aspirin upon sepsis susceptibility and outcomes have reached varying conclusions. Wiewel, et al. conducted a prospective cohort study using data from 972 ICU patients and found that prior antiplatelet therapy was not associated with severity of sepsis, rates of septic shock, or sepsis mortality [21]. Using a nested cohort study, Al Harbi, et al. found that aspirin use in ICU patients was associated with increased rates of severe sepsis and length of stay [32]. In contrast to these prior studies, our data were not limited by ICU admission and included information on a range of baseline participant characteristics. We were able to define regular aspirin exposure as well as identify sepsis events occurring over a 10-year span. We note that the greatest attenuation of the association between aspirin and first sepsis events occurred after adjusting for demographics and chronic medical conditions, suggesting that aspirin use may be acting as a surrogate marker for comorbid burden.

Of note, we observed no association between baseline aspirin use and sepsis mortality, a finding that contrasts with several prior studies. However, these prior works had important methodological differences [16–19]. Falcone, et al. found that regular aspirin therapy was associated with decreased mortality due to community-acquired pneumonia [33]. However, pneumonia cases reflect only a subset of sepsis cases, and these results may not be generalizable to

### Table 3. Multivariable Cox regression models evaluating associations between aspirin use and first sepsis events. ASA = aspirin.

| Exposure                                | Total N | Event N (%) | Hazard Ratio (HR) (95% CI) | Crude | Model 1 | Model 2 | Model 3 |
|-----------------------------------------|---------|-------------|---------------------------|-------|---------|---------|---------|
| **Baseline ASA**                        |         |             |                           |       |         |         |         |
| No ASA                                  | 16,821  | 748 (4.5)   | Ref                       | Ref   | Ref     | Ref     | Ref     |
| ASA                                     | 12,869  | 778 (6.1)   | 1.35 (1.22–1.49)          | 1.18 (1.07–1.31) | 1.19 (1.07–1.32) | 1.00 (0.90–1.13) |
| **Prior Coronary Artery Disease (CAD)** |         |             |                           |       |         |         |         |
| No ASA                                  | 1,582   | 115 (7.3)   | Ref                       | Ref   | Ref     | Ref     | Ref     |
| ASA                                     | 3,649   | 308 (8.4)   | 1.08 (0.87–1.34)          | 1.05 (0.85–1.31) | 1.08 (0.87–1.35) | 1.09 (0.85–1.40) |
| **Framingham Coronary Heart Disease (CHD) Risk Score** |         |             |                           |       |         |         |         |
| <10%                                    |         |             |                           |       |         |         |         |
| No ASA                                  | 9,745   | 330 (3.4)   | Ref                       | Ref   | Ref     | Ref     | Ref     |
| ASA                                     | 5,325   | 219 (4.1)   | 1.19 (1.01–1.42)          | 1.16 (0.98–1.38) | 1.17(0.99–1.39) | 1.10 (0.91–1.33) |
| 10–20%                                  |         |             |                           |       |         |         |         |
| No ASA                                  | 3,022   | 173 (5.7)   | Ref                       | Ref   | Ref     | Ref     | Ref     |
| ASA                                     | 2,218   | 119 (5.4)   | 0.90 (0.71–1.14)          | 0.94 (0.74–1.18) | 0.97 (0.76–1.22) | 0.89 (0.69–1.15) |
| >20%                                    |         |             |                           |       |         |         |         |
| No ASA                                  | 1,570   | 98 (6.2)    | Ref                       | Ref   | Ref     | Ref     | Ref     |
| ASA                                     | 1,191   | 100 (8.4)   | 1.31 (0.99–1.73)          | 1.29 (0.98–1.71) | 1.27 (0.96–1.69) | 1.14 (0.84–1.57) |

Model 1 = Adjusted for demographics (age, sex, race, region, income, education)  
Model 2 = Model 1 + Health Behaviors (alcohol use, smoking status)  
Model 3 = Model 2 + Chronic Medical Conditions (diabetes, hypertension, dyslipidemia, stroke, coronary artery disease, atrial fibrillation, deep vein thrombosis, peripheral artery disease, chronic kidney disease, chronic lung disease, obesity), hsCRP, ACR, Morisky Adherence Scale  
Models stratified by Framingham CHD Risk Score for these associations are  
Model 1’ = Adjusted for demographics (race, region, income, education)  
Model 2’ = Model 1’ + Health Behaviors (alcohol use)  
Model 3’ = Model 2’ + Chronic Medical Conditions (stroke, coronary artery disease, atrial fibrillation, deep vein thrombosis, peripheral artery disease, chronic kidney disease, chronic lung disease, obesity), hsCRP, ACR, Morisky Adherence Scale

https://doi.org/10.1371/journal.pone.0194829.t003
In a population-based cohort study in Taiwan, Tsai, et al. found that prior antiplatelet use was associated with lower rates of sepsis mortality [15]. However, the study only included antiplatelet use in the 30 days prior to admission, and did not differentiate aspirin from other antiplatelet agents. Similarly, in a meta-analysis, Trauer, et al. observed 7% lower sepsis mortality among pre-existing aspirin users, but most of the included studies did not differentiate between the use of aspirin and other antiplatelet agents [34]. Of note, in our series we observed a sepsis hospital mortality rate of only 9.2%, while the studies in the Trauer, et al. study reported sepsis mortality ranging from 14 to 42%. Thus, the observed associations may be due to the higher acuity sepsis populations included in the study.

Aspirin has multiple effects in critically ill patients as an antiplatelet drug to inhibit platelet function to depress interaction of inflammatory mediators with immune cells therefore modulates the adverse effects associated with the inflammatory reactions [35–37]. In addition, aspirin stimulates the synthesis of nitric oxide that inhibits the interactions between cells, and decreases poly-morph neutrophil recruitment [38]. The lack of beneficial effect of aspirin may be a reflection of the interaction on these multiple pathways.

For the past decade, research and management efforts have been focused on the acute care of sepsis and infection. However, prevention can be a very powerful management strategy. Societal rates of MI, stroke, or cardiovascular disease mortality have been mitigated by

Fig 1. Kaplan Meier curve for first sepsis events, stratified by baseline aspirin use.

https://doi.org/10.1371/journal.pone.0194829.g001
organized prevention efforts [39]. In prior studies we have identified a host of novel risk factors associated with sepsis susceptibility [40]. Additional study must identify other potential interventions to limit and reduce long-term rates of sepsis.

Limitations

We assumed that aspirin use was continuous throughout the 10-year follow-up period; true aspirin use may have fluctuated over time. In order to address the effects of variations in aspirin use, we controlled for medication adherence in our analyses. We used various methods to adjust for possible confounding by indication, but there could have been additional factors associated with aspirin use omitted from the analysis. We also did not have information on the indications for aspirin use. We surmised that aspirin use was for prevention of coronary heart disease, but participants may have taken aspirin for stroke prophylaxis or analgesia.

REGARDS includes only African American and White participants. We were able to obtain data on the presence or absence of chronic medical conditions, but not disease severity. The data did not include any information on immunocompromised participants. As the focus of our study was on community-acquired sepsis, we did not include cases of sepsis that occurred during hospital stay. Some participants were not admitted to the hospital and were treated only in the Emergency Department, but we reviewed their medical records to confirm that these events fulfilled sepsis criteria. We may not have been able to detect all sepsis events as REGARDS is not a surveillance study. We observed a sepsis death rate (9%) that is lower than in other studies.

Conclusion

Aspirin use was not associated with long-term rates of sepsis in the REGARDS cohort.
Supporting information

S1 Table. Detailed definitions and technical information for sociodemographics, health behaviors, chronic medical conditions and biomarkers.
(DOCX)

S2 Table. Morisky medication adherence scale.
(DOCX)

Acknowledgments

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. Representatives of the funding agencies have been involved in the review of the manuscript but not directly involved in the collection, management, analysis or interpretation of the data.

This study was supported by award R01-NR012726 from the National Institute for Nursing Research, UL1-RR025777 from the National Center for Research Resources, as well as by grants from the Center for Clinical and Translational Science and the Lister Hill Center for Health Policy of the University of Alabama at Birmingham.

The parent REGARDS study was supported by cooperative agreement U01-NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Service.

Ms. Hsu received support from TL1TR001418 from the National Center For Advancing Translational Sciences of the National Institutes of Health.

Mr. Donnelly received support from 1F31GM122180 from the National Institute of General Medical Sciences. Mr. Moore received grant support from R25-CA4788 funded by the National Cancer Institute.

The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions can be found at http://www.regardsstudy.org and http://www.regardssepsis.org.

Author Contributions

Conceptualization: Joann Hsu, John P. Donnelly, Ninad S. Chaudhary, Henry E. Wang.

Data curation: John P. Donnelly, Monika M. Safford, Henry E. Wang.

Formal analysis: Joann Hsu, John P. Donnelly, Ninad S. Chaudhary, Justin X. Moore, Henry E. Wang.

Funding acquisition: Monika M. Safford, Henry E. Wang.

Methodology: Joann Hsu, John P. Donnelly, Justin X. Moore, Henry E. Wang.

Project administration: Henry E. Wang.

Resources: Henry E. Wang.

Validation: Junghyun Kim.

Writing – original draft: Joann Hsu.

Writing – review & editing: Joann Hsu, John P. Donnelly, Ninad S. Chaudhary, Justin X. Moore, Monika M. Safford, Junghyun Kim, Henry E. Wang.
References

1. Singer M, Deutschman CS, Seymour CW, Shankar-Haris M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA: the journal of the American Medical Association. 2016; 315(8):801–10. https://doi.org/10.1001/jama.2016.0287 PMID: 26903338

2. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013; 369(21):2063.

3. Wang HE, Jones AR, Donnelly JP. Revised National Estimates of Emergency Department Visits for Sepsis in the United States. Crit Care Med. 2017; 45(9):1443–9. https://doi.org/10.1097/CCM.0000000000002538 PMID: 28817480

4. Gupta RG, Hartigan SM, Kashiaris MG, Sessler CN, Bearman GM. Early goal-directed resuscitation of patients with septic shock: current evidence and future directions. Crit Care. 2015; 19:286. https://doi.org/10.1186/s13054-015-1011-9 PMID: 26316210

5. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39(2):165–228. https://doi.org/10.1007/s00134-012-2769-8 PMID: 23361625

6. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003; 110(5–6):255–8. PMID: 14592543

7. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 1997; 23(4):349–56. https://doi.org/10.1055/s-2007-996108 PMID: 9263351

8. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Circulation. 2016.

9. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr., Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Catheter Cardiovasc Interv. 2013; 82(1):E1–27. https://doi.org/10.1002/ccd.24776 PMID: 23299937

10. Ittaman SV, VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res. 2014; 12(3–4):147–54. https://doi.org/10.3121/cmr.2013.1197 PMID: 24573704

11. Zhang Q, Wang C, Zheng M, Li Y, Li J, Zhang L, et al. Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. Cerebrovasc Dis. 2015; 39(1):13–22. https://doi.org/10.1159/000369778 PMID: 25547900

12. Yaguchi A, Lobo FL, Vincent JL, Pradier O. Platelet function in sepsis. J Thromb Haemost. 2004; 2(12):2096–102. https://doi.org/10.1111/j.1538-7836.2004.01009.x PMID: 15613012

13. Saracco P, Vitale P, Scolfaro C, Pollio B, Pagliarino M, Timeus F. The coagulopathy in sepsis: significance and implications for treatment. Pediatr Rep. 2011; 3(4):e30. https://doi.org/10.4081/pr.2011.e30 PMID: 22355515

14. Satran R, Almog Y. The coagulopathy of sepsis: pathophysiology and management. Isr Med Assoc J. 2003; 5(7):516–20. PMID: 12901250

15. Tsai MJ, Ou SM, Shih CJ, Chao PW, Wang LF, Shih YN, et al. Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study. Intensive Care Med. 2015; 41(5):806–13. https://doi.org/10.1007/s00134-015-3760-y PMID: 25829229

16. Sossdorf M, Otto GP, Boettle J, Winning J, Losche W. Benefit of low-dose aspirin and non-steroidal anti-inflammatory drugs in septic patients. Crit Care. 2013; 17(1):402. https://doi.org/10.1186/cc11886 PMID: 23294562

17. Eisen DP, Reid D, McBryde ES. Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis. Crit Care Med. 2012; 40(6):1761–7. https://doi.org/10.1097/CCM.0b013e3182469df PMID: 22610182

18. Toner P, McCauley DF, Shyamsundar M. Aspirin as a potential treatment in sepsis or acute respiratory distress syndrome. Crit Care. 2015; 19:432. https://doi.org/10.1186/s13054-015-1091-6 PMID: 26494395

19. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthey MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest. 2009; 119(1):3450–61. https://doi.org/10.1172/JCI38432 PMID: 19809160

20. Valerio-Rojas JC, Jaffer IJ, Kor DJ, Gajic O, Cartin-Ceba R. Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study. Crit Care Res Pract. 2013; 2013:782573. https://doi.org/10.1155/2013/782573 PMID: 23509620

21. Wiewel MA, de Stoppelaar SF, van Vught LA, Frencken JF, Hoogendijk AJ, Klein Kluw Bergen PM, et al. Chronic antiplatelet therapy is not associated with alterations in the presentation, outcome, or host
response biomarkers during sepsis: a propensity-matched analysis. Intensive Care Med. 2016; 42(3):352–60. https://doi.org/10.1007/s00134-015-4171-9 PMID: 26768440

22. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005; 25(3):135–43. https://doi.org/10.1159/000086678 PMID: 15990444

23. Wang HE, Shapiro NI, Safford MM, Griffin R, Judd S, Rodgers JB, et al. High-sensitivity C-reactive protein and risk of sepsis. PLoS One. 2013; 8(7):e69232. https://doi.org/10.1371/journal.pone.0069232 PMID: 23935961

24. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000; 58(4):1758–64. https://doi.org/10.1111/j.1523-1755.2000.00337.x PMID: 11012910

25. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical care. 1986; 24(1):67–74. PMID: 3945130

26. Ford ES, Giles WH, Mokdad AH. The distribution of 10-Year risk for coronary heart disease among U.S. adults. Journal of the American College of Cardiology. 2004; 43(10):1791–6. https://doi.org/10.1016/j.jacc.2003.11.061 PMID: 15145101

27. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17(19):2265–81. PMID: 9802183

28. McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf. 2003; 12(7):551–8. https://doi.org/10.1002/pds.14558178

29. Rubin DB. Bias Reduction Using Mahalanobis-Metric Matching. Biometrics. 1980; 36(2):293–98.

30. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011; 10(2):150–61. https://doi.org/10.1002/pst.433 PMID: 20925139

31. Rosenbaum PR, Rubin, Donald B. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score. Journal of the American Statistical Association. 1984; 79:516–24.

32. Al Harbi SA, Tamim HM, Al-Dorzi HM, Sadat M, Arabi YM. Association between aspirin therapy and the outcome in critically ill patients: a nested cohort study. BMC Pharmacol Toxicol. 2016; 17:5. https://doi.org/10.1186/s40360-016-0047-z PMID: 28850706

33. Falcone M, Russo A, Cangemi R, Farcomeni A, Calvieri C, Barilla F, et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am Heart Assoc. 2015; 4(1):e001595. https://doi.org/10.1161/JAHA.114.001595 PMID: 25564372

34. Trauer J, Muhi S, McBryde ES, Al Harbi SA, Arabi YM, Boyle AJ, et al. Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching. Crit Care Med. 2017; 45(11):1871–9. https://doi.org/10.1097/CCM.0000000000002654 PMID: 28799949

35. McEver RP. Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol. 2002; 14(5):581–6. PMID: 12331353

36. Evangelista V, Manarini S, Dell’Elba G, Martelli N, Napoleone E, Di Santo A, et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost. 2005; 94(3):568–77. PMID: 16268474

37. Garcia CC, Guabiraba R, Soriani FM, Teixeira MM. The development of anti-inflammatory drugs for infectious diseases. Discov Med. 2010; 10(55):479–88. PMID: 21189219

38. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med. 2004; 200(1):69–78. https://doi.org/10.1084/jem.20040566 PMID: 15238606

39. Hennekens CH, Dalen JE. Aspirin in the primary prevention of cardiovascular disease: current knowledge and future research needs. Trends Cardiovasc Med. 2014; 24(8):360–6. https://doi.org/10.1016/j.tcm.2014.06.006 PMID: 25444455

40. Wang HE, Donnelly JP, Griffin R, Levan EB, Shapiro NI, Howard G, et al. Derivation of Novel Risk Prediction Scores for Community-Acquired Sepsis and Severe Sepsis. Crit Care Med. 2016; 44(7):1285–94. https://doi.org/10.1097/CCM.0000000000001666 PMID: 27031381